info@birdgroup.be

Login

Research papers

N Engl J Med . 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585.
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease

Lancet Gastroenterol Hepatol. 2024 June vol 9, issue 6, p521-538
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study

Clin Gastroenterol Hepatol . 2024 May 22:S1542-3565(24)00492-0. doi: 10.1016/j.cgh.2024.05.017
RIGOROUS DONOR SELECTION FOR FMT IN ACTIVE ULCERATIVE COLITIS: KEY LESSONS FROM A RANDOMIZED CONTROLLED TRIAL HALTED FOR FUTILITY

Gastroenterology. 2024 May;166(5):802-814.e18
Histologic Remission in Inflammatory Bowel Disease and Female Fertility: A Nationwide Study

Dig Liver Dis. 2024 Apr 6:S1590-8658(24)00312-8. doi: 10.1016/j.dld.2024.03.010. Online ahead of print. PMID: 38584033
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus

Lancet Gastroenterol Hepatol. 2024 Feb 21:S2468-1253(24)00034-7. doi: 10.1016/S2468-1253(24)00034-7
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE)

The American journal of gastroenterology, 22 Jan. 2024, doi:10.14309/ajg.0000000000002635
Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial

Gastroenterology, 2023 Dec 12 doi:10.1053/j.gastro.2023.11.304
Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease

‹
1
2
3
4
›